What is the recommended Vladonix dosage?

Vladonix dosing varies by experience level. Beginners typically start at 10mg daily, moderate users at 20mg 2x daily, and aggressive protocols use 20mg 3x daily.

How do you reconstitute Vladonix?

Vladonix comes as a pre-filled device — no reconstitution needed.

What is the half-life of Vladonix?

The half-life of Vladonix is Unknown (oral peptide complex). This determines how frequently you need to dose for consistent blood levels.

Vladonix

ImmuneOralResearchGrade CUnknown (oral peptide complex) half-life

Thymus BioregulatorImmune RestorationOral PeptideKhavinsonT-Cell Modulation4 weeks on / 12 weeks off

Benefits

Normalizes T-cell counts and CD4/CD8 ratios in clinical observations

Supports thymus gland function during age-related immune decline

Oral capsule — no injections or reconstitution required

Short treatment courses with effects persisting for months

No reported side effects or drug dependence in clinical studies

Can be combined with other symptomatic and pathogenetic therapies

Half-Life

Unknown

Route

Oral

Frequency

Daily

Vial Sizes

20mg, 60mg

BAC Water

Pre-filled

Safety Grade

Grade C

Open Vladonix Dosage Calculator

Calculate exact syringe units for your vial and dose

About Vladonix

Vladonix is a natural thymus peptide bioregulator developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It contains peptide complex A-6, a mixture of low-molecular-weight peptides (under 10 kDa) extracted from the thymus glands of young calves. The product targets thymic tissue to support T-cell maturation and restore age-related immune decline. In a clinical study of 42 patients aged 34-65, Vladonix normalized impaired immune parameters in 78% of cases. The strongest effects were seen in T-lymphocyte subpopulations — CD3+ and CD4+ counts increased reliably, and the CD4+/CD8+ ratio returned to normal ranges. B-cell parameters showed more modest changes. Vladonix isn't a single defined peptide like Thymosin Alpha 1. It's a complex extract containing multiple short peptides that are thought to interact with DNA promoter regions in immune cells, influencing gene expression tied to T-cell differentiation and cytokine balance. This mechanism is consistent with Khavinson's broader bioregulation theory, where tissue-specific peptides act as epigenetic modulators. The product has been used in Russian clinical practice alongside other Khavinson bioregulators for over two decades. It's taken orally as capsules, doesn't require injection, and has shown no reported side effects or drug dependence in clinical observations. Evidence remains limited to Russian and Eastern European studies, and it hasn't undergone Western regulatory review.

Who Should Consider Vladonix

Adults over 50 experiencing age-related immune decline (immunosenescence)
Individuals with frequent or recurrent infections seeking immune support
Those who prefer oral peptides over injectable protocols
Post-illness recovery where immune restoration is desired
People interested in Khavinson bioregulator protocols for longevity

How Vladonix Works

Vladonix delivers a mixture of short thymus-derived peptides (peptide complex A-6) that are absorbed through the GI tract and reach target immune cells. According to Khavinson's bioregulation model, these low-molecular-weight peptides bind to specific DNA sequences in the promoter regions of immune-related genes, modulating transcription in thymic epithelial cells and T-lymphocyte precursors. The peptide complex activates T-lymphocyte maturation, regulates the balance between T-helper (CD4+) and T-suppressor (CD8+) cells, and normalizes immunological reactivity. It also stimulates regeneration in thymic tissue that has undergone age-related involution. The net effect is restoration of cellular immunity parameters — particularly T-cell subpopulations and their functional activity — without overstimulating the immune response. This mechanism overlaps with that of injectable Thymalin (the parent extract) and its synthetic dipeptide derivative Thymogen (L-Glu-L-Trp), though Vladonix uses the oral route and contains a broader peptide fraction.

What to Expect

Days 1-7

Course initiation. No noticeable changes expected. Peptides begin interacting with immune cell gene expression. Establish consistent daily dosing with meals.

Days 8-15

Early immune modulation underway. Some users report improved energy and fewer minor symptoms. T-cell precursor differentiation may be accelerating at the cellular level.

Days 16-30

Clinical studies showed measurable improvements in CD3+, CD4+ counts and CD4/CD8 ratios by this point. 78% of patients experienced normalized immune parameters. Complete the full 30-day course.

Weeks 5-12

post-course

Immune improvements continue to develop after the course ends. Reduced frequency of acute respiratory infections reported in observational data. Benefits persist without continued dosing.

Months 3-6

maintenance

Sustained immune benefits from a single course. Next course typically administered at the 3-6 month mark depending on individual needs and practitioner guidance.

Dosing Protocol

Level	Dose / Injection	Frequency
Beginner	10mg	Daily
Moderate	20mg	2x Daily
Aggressive	20mg	3x Daily

Note: Thymus peptide bioregulator from the Khavinson line. Contains peptide complex A-6 derived from calf thymus. Standard protocol is 1-2 capsules daily for 30 days, repeated every 3-6 months. Oral capsule — no reconstitution needed.

How to Inject Vladonix

Take 1-2 capsules with meals, 1-2 times daily. No reconstitution or injection required. Swallow whole with water. A standard course lasts 15-30 days and can be repeated every 3-6 months. For intensive protocols, some practitioners recommend 2 capsules twice daily for the first 30 days, then 2 capsules daily for 10 days each subsequent month.

Cycling Protocol

On Period

4 weeks

Off Period

12 weeks

Standard bioregulator protocol: 1-2 capsules daily for 30 days, then repeat every 3-6 months. Some protocols use a 10-day intensive course for maintenance. Effects persist well beyond the active dosing period.

Pharmacokinetics

Half-Life

Bioavailability

Oral: unknown; likely low for individual peptide fragments

Tmax

Unknown — no formal PK studies

Data Confidence

low

Source: Estimated from general short peptide pharmacokinetics; no Vladonix-specific PK data published. Oral bioregulator peptides are rapidly degraded.

Pharmacokinetics — Active Dose Over Time

Loading the interactive decay curve.

Side Effects

No side effects or complications were reported in clinical studies. Non-toxic at recommended doses. Not recommended for pregnant or breastfeeding women. As with all bovine-derived products, individuals with allergies to animal proteins should use caution.

Contraindications

Pregnancy or breastfeeding — no safety data in these populations
Known allergy to bovine-derived biological products
Active autoimmune conditions requiring immunosuppressive therapy
Organ transplant recipients on anti-rejection medications
Children under 18 — not studied in pediatric populations

Drug Interactions

Immunosuppressants (tacrolimus, cyclosporine, mycophenolate) — Vladonix may counteract immunosuppressive effects by stimulating T-cell activity
Other thymic peptides (Thymosin Alpha 1, Thymalin, Thymogen) — overlapping mechanisms; avoid concurrent use without medical guidance
Corticosteroids — high-dose steroids may blunt the immunostimulatory effects of Vladonix
Vaccines — timing may need adjustment; immune modulation could alter the response to vaccination